New aromatase inhibitors: More selectivity, less toxicity, unfortunately, the same activity

This publication has 11 references indexed in Scilit:

• A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
  European Journal Of Cancer, 1996
• Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer
  Cancer, 1995
• Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague–Dawley rats
  Carcinogenesis: Integrative Cancer Research, 1994
• Formestane
  Drugs, 1993
• A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
  Journal of Clinical Oncology, 1992
• Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
  Journal of Clinical Oncology, 1990
• Aromatase inhibition by the antifungal ketoconazole
  Journal of Steroid Biochemistry, 1988
• Endogenous oestradiol-17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: Relationship to receptor content
  Published by Elsevier ,1980
• V. Contributions to the physiology of mammalian reproduction. Part I.—The œstrous cycle in the dog. Part II.—The ovary as an organ of internal secretion
  Philosophical Transactions of the Royal Society of London. Series B, Containing Papers of a Biological Character, 1906
• ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1
  The Lancet, 1896